UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 360

Sortiert nach

It All Depends on the Dose: Poisons and Medicines in European History

1st, 2018

Volltextzugriff (PDF)

N-glycan profiling of tissue samples to aid breast cancer subtyping

Scientific reports, 2024-01, Vol.14 (1), p.320-320, Article 320

2024

Volltextzugriff (PDF)

FoxP3 Expression in Tumor-Infiltrating Lymphocytes as Potential Predictor of Response to Immune Checkpoint Inhibitors in Patients with Advanced Melanoma and Non-Small Cell Lung Cancer

Cancers, 2023-03, Vol.15 (6), p.1901

2023

Volltextzugriff (PDF)

How Different Are the Molecular Mechanisms of Nodal and Distant Metastasis in Luminal A Breast Cancer?

Cancers, 2020-09, Vol.12 (9), p.2638

2020

Volltextzugriff (PDF)

Medicine, Natural Philosophy and Religion in Post-Reformation Scandinavia

1st edition., 2017

Volltextzugriff (PDF)

Preoperative Chemoradiotherapy for Gastroesophageal Junction Adenocarcinoma Modified by PET/CT: Results of Virtual Planning Study

Medicina (Kaunas, Lithuania), 2021-12, Vol.57 (12), p.1334

2021

Volltextzugriff (PDF)

PET/CT-tailored treatment of locally advanced oesophago-gastric junction adenocarcinoma: a report on the feasibility of the multicenter GastroPET study

Therapeutic advances in medical oncology, 2021-12, Vol.13, p.17588359211065153

2021

Volltextzugriff (PDF)

Centres of medical excellence: Medical travel and education in Europe, 1500 - 1789

2010

Volltextzugriff (PDF)

484 Preliminary efficacy of the IL-15 superagonist SO-C101 in combination with pembrolizumab in patients with advanced/metastatic solid tumors

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A514-A514

2021

Volltextzugriff (PDF)

Focal necrosis mimicking breast cancer following coronary bypass grafting

World journal of surgical oncology, 2017-05, Vol.15 (1), p.111-111, Article 111

2017

Volltextzugriff (PDF)

The World of Worm

Grell, Ole Peter

1, 2022

Volltextzugriff (PDF)

Phase II study of the anti-TGF-β monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS4173-TPS4173

2021

Volltextzugriff (PDF)

Interim safety and efficacy results from AURELIO-03: A phase 1 dose escalation study of the IL-2/IL-15 receptor βγ superagonist SOT101 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.2502-2502

2022

Volltextzugriff (PDF)

mmunotherapy in the treatment of non-small cell lung cancer

Klinická onkologie, 2021-05, Vol.34 (Suppl 1)

2021

Volltextzugriff (PDF)

Tumor Expression of miR-10b, miR-21, miR-143 and miR-145 Is Related to Clinicopathological Features of Gastric Cancer in a Central European Population

Anticancer research, 2018-06, Vol.38 (6), p.3719-3724

2018

Volltextzugriff (PDF)

The role of multidisciplinary team and molecular tumor board in the treatment of a patient with lung cancer

Klinická onkologie, 2021-05, Vol.34 (Suppl 1)

2021

Volltextzugriff (PDF)

Factors associated with effectiveness of trifluridine/tipiracil versus regorafenib in patients with pretreated metastatic colorectal cancer (mCRC)

Journal of clinical oncology, 2020-02, Vol.38 (4_suppl), p.137-137

2020

Volltextzugriff (PDF)

Uroscopy in Early Modern Europe

Stolberg, Michael

1, 2015

Volltextzugriff (PDF)

TAS-102 in metastatic colorectal cancer (mCRC) - predictive and prognostic factors in a European patient population

Annals of oncology, 2018-10, Vol.29, p.vii74-vii74

2018

Volltextzugriff (PDF)

Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors

Onkologie (Olomouc), 2020-11, Vol.14 (5), p.205-212

2020

Volltextzugriff (PDF)

Prediction of trifluridine/tipiracil (TAS-102) effectiveness in patients with refractory metastatic colorectal cancer (mCRC): Real-life data from the Czech Republic

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e15102-e15102

2019

Volltextzugriff (PDF)

GastroPET: Phase II academic clinical trial evaluating sequential FDG-PET driven preoperative treatment strategy in locally advanced oesophago-gastric cancer in the context of miRNA- and immune-based biomarkers

Journal of clinical oncology, 2018-02, Vol.36 (4_suppl), p.TPS202-TPS202

2018

Volltextzugriff (PDF)

Factors associated with efficacy of TAS-102 in patients with refractory metastatic colorectal cancer (mCRC)

Journal of clinical oncology, 2018-02, Vol.36 (4_suppl), p.858-858

2018

Volltextzugriff (PDF)

1 – 25 von 360

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(284)
Mit Volltextzugriff
(338)

Publikationsform

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

It All Depends on the Dose: Poisons and Medicines in European History

N-glycan profiling of tissue samples to aid breast cancer subtyping

FoxP3 Expression in Tumor-Infiltrating Lymphocytes as Potential Predictor of Response to Immune Checkpoint Inhibitors in Patients with Advanced Melanoma and Non-Small Cell Lung Cancer

How Different Are the Molecular Mechanisms of Nodal and Distant Metastasis in Luminal A Breast Cancer?

Medicine, Natural Philosophy and Religion in Post-Reformation Scandinavia

Preoperative Chemoradiotherapy for Gastroesophageal Junction Adenocarcinoma Modified by PET/CT: Results of Virtual Planning Study

PET/CT-tailored treatment of locally advanced oesophago-gastric junction adenocarcinoma: a report on the feasibility of the multicenter GastroPET study

Centres of medical excellence: Medical travel and education in Europe, 1500 - 1789

484 Preliminary efficacy of the IL-15 superagonist SO-C101 in combination with pembrolizumab in patients with advanced/metastatic solid tumors

Focal necrosis mimicking breast cancer following coronary bypass grafting

The World of Worm

Phase II study of the anti-TGF-β monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC)

Interim safety and efficacy results from AURELIO-03: A phase 1 dose escalation study of the IL-2/IL-15 receptor βγ superagonist SOT101 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors

mmunotherapy in the treatment of non-small cell lung cancer

Tumor Expression of miR-10b, miR-21, miR-143 and miR-145 Is Related to Clinicopathological Features of Gastric Cancer in a Central European Population

The role of multidisciplinary team and molecular tumor board in the treatment of a patient with lung cancer

Phase II study (daNIS-1) of the anti–TGF-β monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC)

Factors associated with effectiveness of trifluridine/tipiracil versus regorafenib in patients with pretreated metastatic colorectal cancer (mCRC)

Uroscopy in Early Modern Europe

TAS-102 in metastatic colorectal cancer (mCRC) - predictive and prognostic factors in a European patient population

Phase II study (daNIS-1) of the anti-TGF-β monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC)

Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors

Prediction of trifluridine/tipiracil (TAS-102) effectiveness in patients with refractory metastatic colorectal cancer (mCRC): Real-life data from the Czech Republic

GastroPET: Phase II academic clinical trial evaluating sequential FDG-PET driven preoperative treatment strategy in locally advanced oesophago-gastric cancer in the context of miRNA- and immune-based biomarkers

Factors associated with efficacy of TAS-102 in patients with refractory metastatic colorectal cancer (mCRC)

Suchergebnisse filtern